

Fiona A Miller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9552694/publications.pdf>

Version: 2024-02-01

107
papers

2,356
citations

186265

28
h-index

276875

41
g-index

108
all docs

108
docs citations

108
times ranked

3011
citing authors

#	ARTICLE	IF	CITATIONS
1	The Consultant's intermediary role in the regulation of molecular diagnostics in the US. <i>Social Science and Medicine</i> , 2022, 304, 112929.	3.8	4
2	Multidisciplinary perspectives on the regulation of diagnostic technologies. <i>Social Science and Medicine</i> , 2022, 304, 115059.	3.8	1
3	Vulnerability of the medical product supply chain: the wake-up call of COVID-19. <i>BMJ Quality and Safety</i> , 2021, 30, 331-335.	3.7	50
4	Measuring clinical utility in the context of genetic testing: a scoping review. <i>European Journal of Human Genetics</i> , 2021, 29, 378-386.	2.8	12
5	Industry, experts and the role of the "invisible college"™ in the dissemination of non-invasive prenatal testing in the US. <i>Social Science and Medicine</i> , 2021, 270, 113635.	3.8	8
6	Policy Rogue or Policy Entrepreneur? The Forms and Impacts of "Joined-Up Governance" for Child Health. <i>Children</i> , 2021, 8, 221.	1.5	1
7	The federal spending power: Building forward after the pandemic. <i>Healthcare Management Forum</i> , 2021, 34, 260-265.	1.4	0
8	Anticipating the primary care role in genomic medicine: expectations of genetics health professionals. <i>Journal of Community Genetics</i> , 2021, 12, 559-568.	1.2	4
9	Moving toward responsible value creation: Business model challenges faced by organizations producing responsible health innovations. <i>Journal of Product Innovation Management</i> , 2021, 38, 548-573.	9.5	19
10	Mitigating Health Care's Contribution to the Climate Crisis. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2021, 47, 609-611.	0.7	1
11	Comparison of outpatient coverage in Canada: Assistive and medical devices. <i>Health Policy</i> , 2021, 125, 1536-1542.	3.0	1
12	Anticipatory governance and moral imagination: Methodological insights from a scenario-based public deliberation study. <i>Technological Forecasting and Social Change</i> , 2020, 151, 119800.	11.6	28
13	The innovation impacts of public procurement offices: The case of healthcare procurement. <i>Research Policy</i> , 2020, 49, 104075.	6.4	20
14	Dry powder inhalers are environmentally preferable to metered-dose inhalers. <i>Cmaj</i> , 2020, 192, E846-E846.	2.0	2
15	Responses to "Health Canada needs to act on laboratory-developed diagnostics". <i>Cmaj</i> , 2020, 192, E261-E261.	2.0	0
16	Half a Century of Wilson & Jungner: Reflections on the Governance of Population Screening. <i>Wellcome Open Research</i> , 2020, 5, 158.	1.8	18
17	Leveraging Our Strengths to Achieve Sustainable Healthcare. <i>HealthcarePapers</i> , 2020, 19, 75-81.	0.3	1
18	Toward a Sustainable Health System: A Call to Action. <i>HealthcarePapers</i> , 2020, 19, 9-25.	0.3	7

#	ARTICLE	IF	CITATIONS
19	“Intervening early”: agendas and rationalisations for children’s developmental health. Evidence and Policy, 2020, 16, 413-428.	1.0	1
20	Half a Century of Wilson & Jungner: Reflections on the Governance of Population Screening. Wellcome Open Research, 2020, 5, 158.	1.8	6
21	Modes of coordination for health technology adoption: Health Technology Assessment agencies and Group Procurement Organizations in a polycentric regulatory regime. Social Science and Medicine, 2020, 265, 113528.	3.8	4
22	Genetic counselors' preferences for coverage of preimplantation genetic diagnosis: A discrete choice experiment. Clinical Genetics, 2019, 95, 684-692.	2.0	2
23	How is patient-centred care addressed in women’s health? A theoretical rapid review. BMJ Open, 2019, 9, e026121.	1.9	25
24	How Procurement Judges The Value of Medical Technologies: A Review of Healthcare Tenders. International Journal of Technology Assessment in Health Care, 2019, 35, 50-55.	0.5	26
25	Dangerous diagnostics? Regulatory reform in the genomic era. BMJ: British Medical Journal, 2019, 364, l640.	2.3	8
26	Informing Integration of Genomic Medicine Into Primary Care: An Assessment of Current Practice, Attitudes, and Desired Resources. Frontiers in Genetics, 2019, 10, 1189.	2.3	48
27	Health Canada needs to act on laboratory-developed diagnostics. Cmaj, 2019, 191, E1067-E1069.	2.0	8
28	Expanding the clinical role of community pharmacy: A qualitative ethnographic study of medication reviews in Ontario, Canada. Health Policy, 2018, 122, 256-262.	3.0	10
29	Anticipating health innovations in 2030–2040: Where does responsibility lie for the publics?. Public Understanding of Science, 2018, 27, 276-293.	2.8	4
30	Rebalancing health systems toward community-based care: The role of subsectoral politics. Health Policy, 2018, 122, 1260-1265.	3.0	12
31	Public involvement and health research system governance: a qualitative study. Health Research Policy and Systems, 2018, 16, 87.	2.8	9
32	Public involvement in health research systems: a governance framework. Health Research Policy and Systems, 2018, 16, 79.	2.8	17
33	DEVELOPMENT OF THE ONTARIO DECISION FRAMEWORK: A VALUES BASED FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT. International Journal of Technology Assessment in Health Care, 2018, 34, 290-299.	0.5	22
34	The institutional workers of biomedical science: Legitimizing academic entrepreneurship and obscuring conflicts of interest. Science and Public Policy, 2018, 45, 404-415.	2.4	5
35	Why Learning How to Chase Butterflies Matters: A Response to Recent Commentaries. International Journal of Health Policy and Management, 2018, 7, 286-287.	0.9	5
36	Insulin pump use and discontinuation in children and teens: a population-based cohort study in Ontario, Canada. Pediatric Diabetes, 2017, 18, 33-44.	2.9	26

#	ARTICLE	IF	CITATIONS
37	A Concurrent Analysis of Three Institutions that Transform Health Technology-Based Ventures: Economic Policy, Capital Investment, and Market Approval. <i>Review of Policy Research</i> , 2017, 34, 636-659.	3.9	7
38	Psychosocial Response to Uncertain Newborn Screening Results for Cystic Fibrosis. <i>Journal of Pediatrics</i> , 2017, 184, 165-171.e1.	1.8	34
39	Managing sickle cell carrier results generated through newborn screening in Ontario: a precedent-setting policy story. <i>Genetics in Medicine</i> , 2017, 19, 625-627.	2.4	5
40	False-Positive Newborn Screening for Cystic Fibrosis and Health Care Use. <i>Pediatrics</i> , 2017, 140, .	2.1	24
41	Understanding relevance of health research: considerations in the context of research impact assessment. <i>Health Research Policy and Systems</i> , 2017, 15, 31.	2.8	26
42	A secondary benefit: the reproductive impact of carrier results from newborn screening for cystic fibrosis. <i>Genetics in Medicine</i> , 2017, 19, 403-411.	2.4	9
43	What's Involved with Wanting to Be Involved? Comparing Expectations for Public Engagement in Health Policy across Research and Care Contexts. <i>Healthcare Policy</i> , 2017, 13, 40-56.	0.6	6
44	Providing Value to New Health Technology: The Early Contribution of Entrepreneurs, Investors, and Regulatory Agencies. <i>International Journal of Health Policy and Management</i> , 2017, 6, 509-518.	0.9	49
45	Resources and population served: a description of the Ontario Paediatric Diabetes Network. <i>CMAJ Open</i> , 2016, 4, E141-E146.	2.4	19
46	Low socioeconomic status is associated with adverse events in children and teens on insulin pumps under a universal access program: a population-based cohort study. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000239.	2.8	29
47	Organizing the entrepreneurial hospital: Hybridizing the logics of healthcare and innovation. <i>Research Policy</i> , 2016, 45, 1534-1544.	6.4	39
48	Parent Experience With False-Positive Newborn Screening Results for Cystic Fibrosis. <i>Pediatrics</i> , 2016, 138, .	2.1	28
49	Informally Regulated Innovation Systems: Challenges for Responsible Innovation in Diagnostics. , 2016, , 227-244.		0
50	The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 12.	2.7	38
51	Using Newborn Screening Bloodspots for Research: Public Preferences for Policy Options. <i>Pediatrics</i> , 2016, 137, .	2.1	11
52	Valuing technology: A qualitative interview study with physicians about insulin pump therapy for children with type 1 diabetes. <i>Health Policy</i> , 2016, 120, 64-71.	3.0	13
53	Child and family experiences with inborn errors of metabolism: a qualitative interview study with representatives of patient groups. <i>Journal of Inherited Metabolic Disease</i> , 2016, 39, 139-147.	3.6	26
54	Governing population screening in an age of expansion: The case of newborn screening. <i>Canadian Journal of Public Health</i> , 2015, 106, e244-e248.	2.3	5

#	ARTICLE	IF	CITATIONS
55	Public Perceptions of the Benefits and Risks of Newborn Screening. <i>Pediatrics</i> , 2015, 136, e413-e423.	2.1	17
56	Expectations and values about expanded newborn screening: a public engagement study. <i>Health Expectations</i> , 2015, 18, 419-429.	2.6	23
57	Citizen expectations of "academic entrepreneurship" in health research: public science, practical benefit. <i>Health Expectations</i> , 2015, 18, 2356-2374.	2.6	8
58	Public views on participating in newborn screening using genome sequencing. <i>European Journal of Human Genetics</i> , 2014, 22, 1248-1254.	2.8	39
59	Genomic testing in cancer: Patient knowledge, attitudes, and expectations. <i>Cancer</i> , 2014, 120, 3066-3073.	4.1	72
60	Parents' Willingness to Pay for Biologic Treatments in Juvenile Idiopathic Arthritis. <i>Value in Health</i> , 2014, 17, 830-837.	0.3	7
61	Examining the ethical and social issues of health technology design through the public appraisal of prospective scenarios: a study protocol describing a multimedia-based deliberative method. <i>Implementation Science</i> , 2014, 9, 81.	6.9	17
62	Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care. <i>European Journal of Human Genetics</i> , 2014, 22, 391-395.	2.8	98
63	Early economic evaluation of emerging health technologies: protocol of a systematic review. <i>Systematic Reviews</i> , 2014, 3, 81.	5.3	19
64	Does a Duty of Disclosure Foster Special Treatment of Genetic Research Participants?. <i>Journal of Genetic Counseling</i> , 2013, 22, 654-661.	1.6	6
65	Parents' Perspectives on Participating in Genetic Research in Autism. <i>Journal of Autism and Developmental Disorders</i> , 2013, 43, 556-568.	2.7	32
66	Horizon 2020 and the need to reinvent health technology development. <i>Lancet, The</i> , 2013, 382, 1402-1403.	13.7	2
67	Reflections on the Cost of "Low-Cost" Whole Genome Sequencing: Framing the Health Policy Debate. <i>PLoS Biology</i> , 2013, 11, e1001699.	5.6	67
68	The Sad Story of Newborn Screening for Krabbe: The Need for Good Governance. <i>Public Health Ethics</i> , 2013, 6, 123-126.	1.0	2
69	Do Canadian Researchers and the Lay Public Prioritize Biomedical Research Outcomes Equally? A Choice Experiment. <i>Academic Medicine</i> , 2013, 88, 519-526.	1.6	12
70	Primary care role in expanded newborn screening: After the heel prick test. <i>Canadian Family Physician</i> , 2013, 59, 861-8.	0.4	7
71	One thing leads to another: the cascade of obligations when researchers report genetic research results to study participants. <i>European Journal of Human Genetics</i> , 2012, 20, 837-843.	2.8	17
72	Reply to Ross' commentary: Reproductive benefit through newborn screening: preferences, policy and ethics. <i>European Journal of Human Genetics</i> , 2012, 20, 486-487.	2.8	6

#	ARTICLE	IF	CITATIONS
73	Citizens' Values Regarding Research With Stored Samples From Newborn Screening in Canada. <i>Pediatrics</i> , 2012, 129, 239-247.	2.1	38
74	What does "respect for persons" require? Attitudes and reported practices of genetics researchers in informing research participants about research. <i>Journal of Medical Ethics</i> , 2012, 38, 48-52.	1.8	14
75	Health-care providers' views on pursuing reproductive benefit through newborn screening: the case of sickle cell disorders. <i>European Journal of Human Genetics</i> , 2012, 20, 498-504.	2.8	18
76	Parents' preferences for drug treatments in juvenile idiopathic arthritis: A discrete choice experiment. <i>Arthritis Care and Research</i> , 2012, 64, 1382-1391.	3.4	26
77	Leveraging the "living laboratory": On the emergence of the entrepreneurial hospital. <i>Social Science and Medicine</i> , 2012, 75, 717-724.	3.8	34
78	Understanding sickle cell carrier status identified through newborn screening: a qualitative study. <i>European Journal of Human Genetics</i> , 2010, 18, 303-308.	2.8	23
79	Reconsidering reproductive benefit through newborn screening: a systematic review of guidelines on preconception, prenatal and newborn screening. <i>European Journal of Human Genetics</i> , 2010, 18, 751-760.	2.8	45
80	What is a meaningful result? Disclosing the results of genomic research in autism to research participants. <i>European Journal of Human Genetics</i> , 2010, 18, 867-871.	2.8	57
81	The primary care physician role in cancer genetics: a qualitative study of patient experience. <i>Family Practice</i> , 2010, 27, 563-569.	1.9	27
82	Consent for Newborn Screening: The Attitudes of Health Care Providers. <i>Public Health Genomics</i> , 2010, 13, 181-190.	1.0	22
83	Reframing norms: boundary maintenance and partial accommodations in the work of academic technology transfer. <i>Science and Public Policy</i> , 2010, 37, 689-701.	2.4	17
84	Ethics in Canadian health technology assessment: A descriptive review. <i>International Journal of Technology Assessment in Health Care</i> , 2009, 25, 463-469.	0.5	32
85	Informing Parents About Expanded Newborn Screening: Influences on Provider Involvement. <i>Pediatrics</i> , 2009, 124, 950-958.	2.1	41
86	Clinical obligations and public health programmes: healthcare provider reasoning about managing the incidental results of newborn screening. <i>Journal of Medical Ethics</i> , 2009, 35, 626-634.	1.8	23
87	Imagining value, imagining users: Academic technology transfer for health innovation. <i>Social Science and Medicine</i> , 2009, 68, 1481-1488.	3.8	30
88	Postal survey of physicians and laboratories: Practices and perceptions of molecular oncology testing. <i>BMC Health Services Research</i> , 2009, 9, 131.	2.2	30
89	Decision-Making About Inherited Cancer Risk: Exploring Dimensions of Genetic Responsibility. <i>Journal of Genetic Counseling</i> , 2009, 18, 252-264.	1.6	32
90	The expansion of newborn screening: is reproductive benefit an appropriate pursuit?. <i>Nature Reviews Genetics</i> , 2009, 10, 666-667.	16.3	19

#	ARTICLE	IF	CITATIONS
91	What does it mean to trust a health system?. Health Policy, 2009, 91, 63-70.	3.0	70
92	Questioning the Consensus: Managing Carrier Status Results Generated by Newborn Screening. American Journal of Public Health, 2009, 99, 210-215.	2.7	33
93	The complex promise of newborn screening. Indian Journal of Medical Ethics, 2009, 6, 142-8.	0.4	6
94	Genetic education for primary care providers: improving attitudes, knowledge, and confidence. Canadian Family Physician, 2009, 55, e92-9.	0.4	69
95	When research seems like clinical care: a qualitative study of the communication of individual cancer genetic research results. BMC Medical Ethics, 2008, 9, 4.	2.4	42
96	Contending visions in the evolution of genetic medicine: The case of cancer genetic services in Ontario, Canada. Social Science and Medicine, 2008, 67, 152-160.	3.8	13
97	Scientists and policy-makers at work: listening to epistemic conversations in a genetics science network. Science and Public Policy, 2008, 35, 207-220.	2.4	6
98	CANADIAN PIONEERS: Remembering Norma Ford Walker. Genome, 2008, 51, vii-viii.	2.0	0
99	What leads to better health care innovation? Arguments for an integrated policy-oriented research agenda. Journal of Health Services Research and Policy, 2008, 13, 251-254.	1.7	54
100	Duty to disclose what? Querying the putative obligation to return research results to participants. Journal of Medical Ethics, 2008, 34, 210-213.	1.8	105
101	The Helix in the Labyrinth: Do We Need Genetic Health Services and Policy Research?. Healthcare Policy, 2008, 4, 30-38.	0.6	1
102	Gene patentsâ€”more evidence needed, but policymakers must act. Nature Biotechnology, 2007, 25, 388-389.	17.5	6
103	Incorporating Documents Into Qualitative Nursing Research. Journal of Nursing Scholarship, 2005, 37, 348-353.	2.4	114
104	Economic Considerations for Health Insurance Coverage of Emerging Genetic Tests. Public Health Genomics, 2003, 6, 61-73.	1.0	20
105	CONFRONTING THE "GRAY ZONES" OF TECHNOLOGY ASSESSMENT: EVALUATING GENETIC TESTING SERVICES FOR PUBLIC INSURANCE COVERAGE IN CANADA. International Journal of Technology Assessment in Health Care, 2003, 19, 301-316.	0.5	36
106	The importance of being marginal: Norma Ford Walker and a Canadian school of medical genetics. American Journal of Medical Genetics Part A, 2002, 115, 102-110.	2.4	18
107	What Place Ethics?. Healthcare Quarterly, 2000, 4, 66-67.	0.7	1